BCR-ABL-IN-5

BCR-ABL-IN-5

• CAS Number: 1795736-60-5
• UNSPSC Description: BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-AblWT and Bcr-AblT3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells[1].
• Target Antigen: Bcr-Abl
• Type: Reference compound
• Related Pathways: Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/bcr-abl-in-5.html
• Solubility: 10 mM in DMSO
• Smiles: NC1=NNC2=C1C(C3=CC=C(C=C3)C(N4CCN(CC4)C(C5=C(C=C(C=C5)Cl)Cl)=O)=O)=CC=C2
• Molecular Weight: 494.37
• References & Citations: [1]Ashraf K El-Damasy, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. Eur J Med Chem. 2020 Dec 1;207:112710.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported